PAI is founded with a focus on health economics and health policy for governmental clients
1978
PAI is awarded a large, multi-year contract with the US National Center for Health Statistics to refine methods for incidence-based cost-of-illness studies
1984
PAI publishes the first cost-effectiveness evaluation of a smoking cessation intervention (in JAMA)
1986
PAI publishes two landmark studies on the cost-effectiveness of prophylaxis against venous thromboembolism in major orthopedic surgery (in JAMA) and abdominal surgery (in American Journal of Medicine)
1987
PAI publishes the first formal cost-effectiveness evaluation of lipid-lowering therapy in adults (in JAMA)
1989
PAI publishes first study of the economic burden of type 2 diabetes (in JAMA)
1990
PAI publishes first risk-benefit study of an Rx-to-OTC switch, in advance of the introduction of OTC H2 receptor antagonists (in Medical Care)
1993
PAI publishes findings from one of the first so-called “pragmatic” clinical trials conducted at a large HMO (in Archives of Internal Medicine)
1994
PAI publishes one of the first cost-effectiveness evaluations of a pediatric vaccine against chicken pox (in Journal of Pediatrics)
1994
PAI publishes study of cost-effectiveness of antiplatelet therapy in preventing stroke in high-risk patients (in Stroke)
1996
PAI publishes landmark study showing that patients who were prescribed terfendine (Seldane) often also frequently received drugs that were mentioned in a black-box warning (in JAMA)
1999
PAI publishes landmark series of studies on US economic burden of obesity (in Archives of Internal Medicine) and economic benefits of weight loss (in American Journal of Public Health)
2003
PAI publishes first RWE study linking use of thiazolidinediones in type 2 diabetes to risk of heart failure (In Diabetes Care)
2005
PAI publishes the first cost-effectiveness evaluation of a pediatric vaccine that incorporates benefits of herd immunity (in Vaccine)
2008
PAI publishes first micro-simulation model of biologic for treatment of rheumatoid arthritis (in Journal of Rheumatology and Rheumatology, respectively)
2008
PAI publishes landmark studies on costs and consequences of failure of first-line antibiotic therapy in skin & skin structure infections (in Infection Control and Hospital Epidemiology) and intra-abdominal infections (in Surgical Infections)
2008
PAI becomes a founding member of the MINERVA Health Economics Network
2009
PAI publishes landmark study at large HMO demonstrating that women who receive bisphosphonates in clinical practice do not experience expected reductions in fracture risk due to poor adherence (in Bone)
2009
PAI publishes landmark study demonstrating large increase in US hospital admissions for skin & skin structure infections with advent of “super bugs” (in Emerging Infectious Diseases)
2010
PAI publishes landmark study on economic costs of opioid abuse (in Clinical Journal of Pain)
2013
PAI publishes 15-year, multi-center observational study on incidence of skeletal complications in patients with metastatic cancer
2015
PAI introduces hēRo 1.0, its revolutionary Web-based platform for health economics modeling that can be accessed from any device with a modern browser connected to the Internet
2017
PAI will introduce hēRo Model Maker 3.0, a revolutionary platform that not only will enable users to run health economics models from any Web-enabled device, but also to build these models in a fraction of the time required in Microsoft Excel